A share price of Mersana Therapeutics Inc [MRSN] is currently trading at $2.53, up 9.05%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRSN shares have gain 10.96% over the last week, with a monthly amount glided 8.12%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, JP Morgan upgraded its rating to Neutral on March 19, 2024, and kept the price target unchanged to $5. On February 29, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $7 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $7 on February 29, 2024. BTIG Research upgraded its rating to a Buy but $6 remained the price target by the analyst firm on February 29, 2024. Citigroup upgraded its rating to Buy for this stock on December 04, 2023, and upped its price target to $5. In a note dated July 28, 2023, Robert W. Baird downgraded an Neutral rating on this stock and revised its target price from $7 to $1.
Mersana Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.22 and $6.28. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $2.53 at the most recent close of the market. An investor can expect a potential return of 18.58% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
Trailing Twelve Months sales for Mersana Therapeutics Inc [NASDAQ:MRSN] were 34.84M which represents 63.65% growth. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -2.28%, Pretax Profit Margin comes in at -2.13%, and Net Profit Margin reading is -2.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -4.01 and Total Capital is -0.78. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 24.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.34 points at the first support level, and at 2.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.64, and for the 2nd resistance point, it is at 2.74.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mersana Therapeutics Inc [NASDAQ:MRSN] is 2.35. Further, the Quick Ratio stands at 2.35, while the Cash Ratio is 1.15. Considering the valuation of this stock, the price to sales ratio is 9.78, the price to book ratio is 296.25.
Transactions by insiders
Recent insider trading involved Bala Mohan, SVP, Chief Development Officer, that happened on Oct 28 ’24 when 1884.0 shares were sold. Officer, Bala, Mohan completed a deal on Oct 28 ’24 to buy 1884.0 shares. Meanwhile, SVP, COO & CFO DeSchuytner Brian sold 8089.0 shares on Oct 02 ’24.
